Skip to main content

Year: 2020

Osisko Windfall Infill Drilling Intersects Some More Gold

TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) — Osisko Mining Inc. (OSK:TSX. “Osisko” or the “Corporation”) is pleased to provide new analytical results from the ongoing expansion and definition drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Québec.Drilling is currently focused on the Lynx deposit. Osisko Chief Executive Officer John Burzynski commented: “Lynx continues to deliver on high-grade and width with consistency, as illustrated by today’s headline intercepts of 193 g/t Au over 2.3 metres and 75.7 g/t Au over 12.3 metres.”The table below contains resource definition infill intercepts located inside the February 2020 mineral resource estimate wireframes (see Osisko news release dated February 19, 2020). Significant new...

Continue reading

Le forage intercalaire d’Osisko à Windfall recoupe encore de l’or

TORONTO, 17 nov. 2020 (GLOBE NEWSWIRE) — Minière Osisko inc. (OSK : TSX, « Osisko » ou la « Société ») a le plaisir de publier de nouveaux résultats d’analyse issus du programme de forage d’expansion et de définition en cours sur le projet aurifère Windfall, entièrement détenu par la Société et situé dans la ceinture de roches vertes de l’Abitibi, dans le canton d’Urban, Eeyou Istchee Baie-James, Québec.Les travaux de forage sont axés sur le gîte Lynx. Le chef de la direction d’Osisko, John Burzynski, a déclaré : « Lynx continue de livrer des teneurs élevées et des épaisseurs intéressantes avec beaucoup de régularité, comme en témoignent les intersections en manchette de 193 g/t Au sur 2,3 mètres et 75,7 g/t Au sur 12,3 mètres. »Le tableau ci-dessous présente les intersections de forage intercalaire du programme de définition des...

Continue reading

National MI Integrates with LONPricer to Streamline Originations

EMERYVILLE, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — National Mortgage Insurance Corporation (National MI), the primary operating subsidiary of NMI Holdings, Inc. (NASDAQ: NMIH), is now integrated with Loan Originator Networks, LLC (LON), which creates websites for mortgage lenders and integrates seamlessly with their loan origination systems (LOS). LON worked with National MI to offer a new functionality that provides National MI’s risk-based pricing engine, RateGPS®, in LONPricer, a comprehensive platform that handles all mortgage channels—retail, wholesale, correspondent, and consumer direct.The integration brings National MI’s innovative, real-time, risk-based mortgage insurance pricing to LONPricer. “National MI is delighted to join forces with LON,” said Norm Fitzgerald, chief sales officer with National MI. “Having access...

Continue reading

Nemaura Medical Launches BEAT™diabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website

LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the re-launch of its corporate website, www.nemauramedical.com, and the website for its flagship program, BEAT™diabetes, www.beatdiabetes.life, which serves as the unofficial launch of the program and allows users to register and learn about participating in an overall health management system to potentially reverse Type 2 diabetes.“The launch of the BEAT™diabetes program website is an important entry into the market to allow consumers to access many of the life management tools that come with the program. In addition to introducing...

Continue reading

Nokia Deepfield identifies 2020 network traffic, internet consumption trends in new intelligence report

Press ReleaseNokia Deepfield identifies 2020 network traffic, internet consumption trends in new intelligence reportImplications for service providers and internet service delivery chain with significant growth in video streaming, gaming, video conferencing and DDoS Data recorded by service providers across Europe and North America from February to September shows 30% increase in video subscribers, 23% increase in VPN end-points in the U.S, 40-50% increase in DDoS traffic17 November 2020Espoo, Finland – Nokia Deepfield has today released its Network Intelligence Report, which examines service provider network traffic and consumption trends in 2020, revealing the networks were made to withstand the internet’s rollercoaster year. The report examines overall changes in internet traffic patterns in the last decade and in 2020, focusing on...

Continue reading

EDAP Announces Exclusive Distribution Agreement with Leading Italian Medical Device Distributor AB Medica

Partnership further extends the availability of EDAP’s High Intensity Focused Ultrasound (HIFU) technology to one of the largest markets in EuropeComplementary to AB Medica’s extensive product portfolio which includes robotic surgery solutions as well as ExactVuLYON, France, November 17, 2020 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive distribution agreement with AB Medica, a leading distribution of medical technologies across Italy.Marc Oczachowski, Chairman and Chief Executive Officer of EDAP, commented: “We are very pleased to partner with AB Medica, a widely recognized leader in Italy for the distribution of cutting-edge medical technologies. This is clearly a step forward for EDAP in its HIFU adoption and commercialization...

Continue reading

Natural Gas Services Group, Inc. Reports Third Quarter 2020 Financial and Operating Results

Midland, TX, Nov. 17, 2020 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment and services to the energy industry, today announced financial results for the three and nine months ended September 30, 2020.Third Quarter 2020 HighlightsCompany generated exceptional cash flow and steady utilization despite market turmoil    Cash balance increased 78% to $27.6 million in Q3 from $15.5 million in Q2 due to strong operating cash flow, reduced CAPEX, and a federal income tax refund of $3.9 million.Cash flows from operating activities increased 31% to $27.9 million during the first nine months of 2020 compared to $21.3 million during the same period in 2019.   Utilization remained steady on both a horsepower (63.8% in Q3 vs. 63.6% in Q2) and a unit...

Continue reading

Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

Spotlight poster on updated PFS and OS data from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancerBUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and encequidar (“oral paclitaxel”) data will be presented in four separate poster presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) to be held virtually December 8-11. Presentations will include, from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer (MBC), a spotlight poster on progression-free survival (PFS) and overall survival (OS), and posters on neuropathy (CIPN), and...

Continue reading

Forecast [2019-2026], Therapeutic Enzymes Market Size, Share, Growth, Trends, Revenue, Competitive Analysis, Report

Pune, India, Nov. 17, 2020 (GLOBE NEWSWIRE) — The global therapeutic enzymes market will rise considerably driven by increasing applications of the product in treatment of critical diseases. According to a report by Fortune Business Insights. Therapeutic enzymes have several applications in treatment of severe diseases. They are either used in conjunction or isolated form. The properties of enzyme therapeutics have attracted massive investments in the research and development of the product in the past few years. The increasing patient pool for leukemia will create the platform for growth for the companies operating in the market.The increasing adoption of sedentary lifestyle habits will result in more conditions and disorders. These factors will have a huge impact on the growth of the overall market in the foreseeable future. According...

Continue reading

Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

– Presented New Positive Interim Data from 4mg Cohort of Phase 2 ACCURACY Study of AL101 for the Treatment of R/M ACC at European Society for Medical Oncology 2020 –– Trial In Progress Poster of Phase 2 TENACITY Study of AL101 Monotherapy in Patients with Notch-activated Triple-Negative Breast Cancer Accepted for Presentation at San Antonio Breast Cancer Virtual Symposium –REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.